Skip to main content

Table 2 VEGFR tyrosine-kinase inhibitors studied as monotherapy or combination therapy in HNSCC

From: An update on angiogenesis targeting in head and neck squamous cell carcinoma

AGENTS

STUDY DESIGN/PHASE

# of PATIENTS

PRIMARY ENDPOINT/OTHER EFFICACY ENDPOINTS

REFERENCE

Sorafenib

 Sorafenib 400 mg twice daily

Single arm, Phase II

Single arm, Phase II

n = 41

n = 27

RR 2%; median PFS 4 mo; median OS 9 mo

RR 4%; median PFS 1.8 mo; median OS 4.2 mo

Williamson, 2010 [15]

Elser, 2007 [16]

Sunitinib

 Sunitinib 37.5 mg daily

Single arm, Phase II

n = 38

Rate of disease control 50%; RR 3%; median PFS 2 mo; median OS 3.4 mo

Machiels, 2010 [17]

 Sunitinib 50 mg daily for 4 weeks on, 2 weeks off

Single arm, Phase II (two cohorts, cohort A: PS 0–1 cohort B: PS 2)

n = 22

Cohort A: RR 8%; median TTP 2 mo; median OS 4.9 mo

Cohort B: RR 0; median TTP 2.5 mo; median OS 4.5 mo

Choong, 2010 [18]

 Sunitinib 50 mg daily for 4 weeks on, 2 weeks off

Single arm, Phase II

n = 17

RR 0; median TTP 2.3 mo; median OS 4 mo

Fountzilas, 2010 [19]

Axitinib

 Axitinib 5 mg twice daily

Single arm, Phase II

n = 30

6-month PFS 30%; RR 7%; median PFS 3.7 months; median OS 10.9 mo

Swiecicki, 2015 [20]

Combination Therapy

 Cetuximab +/− sorafenib

Randomized, Phase II

n = 55

Median PFS 3 mo (cetuximab arm) and 3.2 mo (combination arm)

Gilbert, 2015 [21]

 Docetaxel +/− vandetanib

Randomized, Phase II

n = 29

RR 7% (docetaxel arm) and 13% (combination arm)

Limaye, 2013 [22]

 Carboplatin, paclitaxel, sorafenib

Single arm, Phase II

n = 48

Median PFS 8.5 mo; RR 55%; median OS 22.6 mo

Blumenschein, 2012 [23]

  1. RR overall response rate, PFS progression-free survival, TTP time to progression, PS performance status, mo months